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ABSTRACT
Objective Rare genetic disorders resulting in prenatal or neonatal death are genetically heterogeneous, but testing is
often limited by the availability of fetal DNA, leaving couples without a potential prenatal test for future pregnancies.
We describe our novel strategy of exome sequencing parental DNA samples to diagnose recessive monogenic
disorders in an audit of the ﬁrst 50 couples referred.
Method Exome sequencing was carried out in a consecutive series of 50 couples who had 1 or more pregnancies
affected with a lethal or prenatal-onset disorder. In all cases, there was insufﬁcient DNA for exome sequencing of the
affected fetus. Heterozygous rare variants (MAF < 0.001) in the same gene in both parents were selected for analysis.
Likely, disease-causing variants were tested in fetal DNA to conﬁrm co-segregation.
Results Parental exome analysis identiﬁed heterozygous pathogenic (or likely pathogenic) variants in 24 different
genes in 26/50 couples (52%). Where 2 or more fetuses were affected, a genetic diagnosis was obtained in 18/29 cases
(62%). In most cases, the clinical features were typical of the disorder, but in others, they result from a hypomorphic
variant or represent the most severe form of a variable phenotypic spectrum.
Conclusion We conclude that exome sequencing of parental samples is a powerful strategy with high clinical utility for
the genetic diagnosis of lethal or prenatal-onset recessive disorders. © 2017 The Authors Prenatal Diagnosis published
by John Wiley & Sons Ltd.
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INTRODUCTION
Whole exome sequencing (WES) in the postnatal setting has a
diagnostic yield of 25 to 37%.1–4 Trio exome sequencing is often
considered to be the strategy of choice as this can identify both
inherited and de novo variants but is also the most expensive
and relies on availability of large quantities of good quality
DNA samples for the affected child and both parents. Trio
exome analysis is often not possible for couples with single or
multiple pregnancies affected with rare lethal disorders due
to limited DNA quantity and/or quality of fetal DNA (if only
formalin-ﬁxed parafﬁn-embedded tissue is available), leaving
these couples without a diagnosis and limited reproductive
choices.5 Several studies have demonstrated the utility of
exome sequence analysis for fetuses where DNA quantity is
not limited.6,7 In addition to DNA availability, other factors
make diagnosis difﬁcult in lethal fetal disorders, including the
large number of potential genes, phenotypic variability, and
the difﬁculty in accurately phenotyping a mid-gestation fetus.
Single molecular tests may be guided by the limited
phenotyping available, but testing single genes in a step-wise
manner may exhaust the little fetal material that may be
available. This approach often fails to make a diagnosis, and
ultrasound diagnosis in the second trimester is the only
potential option for many couples, with the consequence of
prolonged uncertainty regarding the pregnancy outcome and
the possibility of a late gestation termination.5,6 Where
multiple pregnancies are affected, the disorders are very likely
to be recessive, and a recurrence risk of at least 25% is given
for each future pregnancy but with no prenatal test available
for future pregnancies.
We previously described a strategy utilizing parental exome
sequencing and the application of a set of ﬁltering criteria as
an alternative method to identify potentially pathogenic
variants in shared genes in unrelated, unaffected parents.5
This strategy saves precious fetal DNA as only a small amount
is used for co-segregation studies. Identiﬁcation of a genetic
diagnosis will enable prenatal diagnosis or preimplantation
genetic diagnosis in subsequent pregnancies. This parental
sequencing strategy has been applied in a recent study of
prenatal-onset cases where the authors describe the approach
as “molecular autopsy by proxy” and report a high diagnostic
yield.7 Following our early work,5 we introduced a diagnostic
service, and the current study is an audit of the ﬁrst 50
couples referred for parental exome sequencing. The couples
had at least 1 fetus affected with severe fetal malformations
or underwent termination of a pregnancy for a severely
disabling disorder. In contrast to our previous report, in this
large case series, the analysis was not limited to unrelated
couples or couples with 2 or more affected pregnancies.
Variants were shortlisted for evaluation by using a
bioinformatics pipeline to identify potentially recessive likely
pathogenic variants in established disease-causing genes that
were consistent with the clinical phenotype. Co-segregation
studies were carried out by using the stored DNA samples
from the affected fetus(es). Here, we highlight the
effectiveness of this strategy and the beneﬁts of integrating
exome sequencing for lethal prenatal disorders into the
diagnostic pathway for these couples.
METHODS
Subjects
The case series was composed of 50 couples who had had 1 or
more fetal/neonatal losses or terminated pregnancies based on
the presence of malformations detected by ultrasound
scanning. Of these, 29 had 2 or more affected pregnancies.
Known consanguinity was reported in 11 couples. Two couples
had offspring that died at birth but were tested with this
method due to limited DNA availability from the affected
babies (cases 31 and 41). The couples were referred for exome
sequencing from centers across the UK and Ireland. All patients
provided informed consent for testing to identify a genetic cause
of the disorder affecting their pregnancies. The clinical
description provided for each case by the referring clinician was
converted to human phenotype ontology (HPO) terms by using
the ontobee browser (http://www.ontobee.org/) and HPO
browser (http://human-phenotype-ontology.github.io/tools.
html). The HPO terms for the case series are shown in Table S1.
Exome library preparation and sequencing
Genomic DNA samples were quantiﬁed according to the
manufacturer’s instructions on the Qubit ﬂuorimeter (Thermo
Fisher Scientiﬁc, Massachusetts, USA) to determine that the
minimum quantity of DNA required, 3000 ng, was available.
The samples were fragmented by using the Bioruptor
(Diagenode, Liège, Belgium) and indexed adaptors ligated
before hybridization with the Agilent SureSelect All Exon
capture kit (v4, v5, or v6) or Agilent SureSelect Focused exome
kit (Santa Clara, CA, USA). Paired-end 100-bp reads were
sequenced on a HiSeq 2500 (Illumina, San Diego, CA, USA)
by using either the standard or the rapid run mode or paired-
end 150-bp reads on the NextSeq500 (Illumina, San Diego,
CA, USA) by using either a mid or high output ﬂow cell.
Approximately 12 whole exomes can be run per ﬂow cell, to
generate at least 60 million reads with >80X mean coverage
and >98% of target bases at ≥20X. Samples were sequenced
in multiple batches as and when samples were received for
diagnostic testing. The Illumina HiSeq FASTQ sequencing
reads were demultiplexed and aligned to the reference
(GRCh37/Hg19) by using BWA-MEM (v0.7.12), converted to
BAM format ﬁle and subjected to duplicate removal by using
Picard (v1.129). GATK (v3.4-46) was used for indel realignment,
variant calling, and quality ﬁltering.
Variant annotation and ﬁltering
Variants were annotated by using Alamut-Batch (v1.4.4), a
variant call format ﬁle was inputted and all SNVs and indels
were annotated by using a range of different variant and
genomic databases, including HGMD Professional.8 A
bioinformatics pipeline was designed in-house to identify
shared genes where both parents had a heterozygous
potentially pathogenic variant and to identify X-linked
recessive variants where appropriate (Figure 1). Variants with
a MAF < 0.0001 (<0.01%) and 0.001 (<0.1%) in Exome
aggregation consortium (ExAC http://exac.broadinstitute.org/
) or the Exome variant server (EVS http://evs.gs.washington.
edu/EVS/) were retained to produce a subset of very rare
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variants and rare variants. Variants were restricted to
nonsynonymous variants, those affecting the conserved splice
sites or those within 50/+10 base pairs of ﬂanking exons
predicted by Alamut-Batch to affect splicing (5 tools were used:
SpliceSiteFinder-like, MaxEntScan, NNSplice [Fruitﬂy],
GeneSplicer, and Human Splicing Finder). Variants annotated
as Pathogenic in HGMD Pro (all cases) or ClinVar (since 2016)
were retained regardless of other ﬁltering criteria. Copy
number variants were identiﬁed by using read depth analysis
with a modiﬁed version of R software package ExomeDepth
(v1.1.8)9 and comparing the test sample against reference
samples. Autosomal recessive variants were identiﬁed where
parents either shared the same heterozygous variant or had
different heterozygous variants in the same gene. Potential X-
linked recessive variants in the mother were also shortlisted
where only male pregnancies were affected. The
bioinformatics pipeline is summarized in Figure 1.
Selection of candidate variants
All genes on the variant shortlist were considered and initially
reviewed via the Online Mendelian Inheritance in Man
database (OMIM https://www.omim.org/) and PubMed
(https://www.ncbi.nlm.nih.gov/pubmed/). Candidate variants
in known disease-causing genes were identiﬁed for further
investigation by comparison with the fetal phenotype. Previous
reports of a variant were determined by using HGMD
professional, ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/)
and Locus-speciﬁc databases. In silico tools were accessed via
Alamut Visual (versions 2.7.2-2.10) to predict pathogenicity of
variants. Likely causative variants identiﬁed in this series were
variants that were reported as likely pathogenic or pathogenic
in the patient’s clinical diagnostic report. We have reviewed
all the variant classiﬁcations by using the recently published
American College of Medical Genetics and Genomics
(ACMG)/Association for Molecular Pathology guidelines.10 In
cases where no likely diagnosis was identiﬁed, we undertook
further analysis of a curated gene panel from PanelApp
(https://bioinfo.extge.co.uk/crowdsourcing/PanelApp/).
Conﬁrmation of results
Possible disease-causing variants identiﬁed in parental DNA
samples were conﬁrmed by PCR/Sanger Sequencing for SNVs
and indels or using the QX200 droplet digital PCR system
(Bio-Rad, Hercules, California, USA) for CNVs. Fetal DNA
samples were tested to establish co-segregation of the
variant(s) with disease. DNA from at least 1 affected fetus (or
neonate) was available for testing for each couple. PCR primer
and droplet digital PCR primer/probe sequences are available
on request.
RNA extraction and reverse transcription
For case 7, total RNA was extracted from PAXgene collection
tubes (PreAnalytiX, Hombrechtikon, Switzerland) by using the
PAXgene Blood miRNA Kit (Qiagen, Hilden, Germany).
Complementary DNA (cDNA) was synthesized by using VILO
SuperScript III RT-PCR system (Thermo Fisher Scientiﬁc,
Massachusetts, USA) and fragment/sequence analysis
performed by using primers designed against IFT122 exon 23
and 25. Products were visualized by electrophoresis on a 2%
agarose gel.
RESULTS
Heterozygous pathogenic or likely pathogenic variants in
both partners were identiﬁed in 26/50 couples (52%), and
where 2 or more fetuses were affected, a genetic diagnosis
was obtained in 18/29 (62%) cases (Table 1 and Figures 2A
Figure 1 Bioinformatics pipeline. The ﬁltering criteria are applied to generate a shortlist of genes in which both parents have a heterozygous
variant meeting the criteria. Abbreviations: VCF (variant call format), MQ (mapping quality), QD2 (quality by depth), MUC (mucin antigen),
HLA (human leukocyte antigen), LINC (LincRNA), MAF (minor allele frequency), ESP (Exome Sequencing Project http://evs.gs.washington.
edu/EVS/), ExAC (Exome Aggregation Consortium http://exac.broadinstitute.org/), and dbSNP (NCBI short genetic variation database
https://www.ncbi.nlm.nih.gov/projects/SNP/). [Colour ﬁgure can be viewed at wileyonlinelibrary.com]
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and 2B). Of the 21 couples with only 1 affected pregnancy, a
diagnosis was determined in 8/21 (38%, Figure 2C). No likely
pathogenic variants were identiﬁed by exome sequencing in
the remaining 24 cases. The phenotypic spectrum for the
cases tested and diagnosed is illustrated in Figure 3. Cases 1
and 2 have been described previously.5 Variants classiﬁed as
pathogenic or likely pathogenic were identiﬁed in 24 different
genes (ASPM, ATAD3A, ATRX, B3GLCT, BBS9, BBS10, CENPJ,
DYNC2H1, ERCC5, ETFA, EXOSC3, FRAS1, GLE1 [n = 2],
IFT122, ITGA8, LRP4, MKS1, MRPS22, NEK9, POMGNT1,
RYR1 [n = 2], SASS6, TMEM67, and TRIP11). Autosomal
recessive inheritance was observed in 25 cases, and there
was 1 family identiﬁed with an X-linked recessive etiology
(ATRX variant in case 11). The hemizygous ATRX variant
was present in 2 affected male fetuses with arthrogryosis
and talipes. Sex reversal was present in 1 fetus. Skewed X-
inactivation (100:0) was observed in their heterozygous
mother. Variants in cases 13, 17, and 18 (compound
heterozygous variants in GLE1, BBS9, and DYNC2H1 genes)
were reported as “likely pathogenic” by using the UK best
practice guidelines (http://www.acgs.uk.com/media/774853/
evaluation_and_reporting_of_sequence_variants_bpgs_june_
2013_-_ﬁnalpdf.pdf) prior to adoption of the ACMG
guidelines. These have since been reviewed by using the
ACMG guidelines that classiﬁes them as variants of uncertain
signiﬁcance (Table S2) but are still felt to be “likely
pathogenic” after clinical discussion. From a total of 41
identiﬁed variants, 9 of the variants identiﬁed were previously
reported in the literature11–23 (Tables 1 and Table S1).
Eleven couples with known consanguinity were included
in the series, and a diagnosis was made in 6/11 (54%) of
these couples. Homozygous variants were identiﬁed in 5
of these couples and compound heterozygous variants in
the sixth.
Copy number variants were identiﬁed as likely disease-
causing in 2 families; an ETFA exon 11 deletion (case 34)
and an ATAD3A exon 3 to 4 deletion (case 41). Four couples
had causative variants in recently discovered genes where
there is only 1 publication or <3 cases previously reported:
ATAD3A, ITGA8, NEK9, and SASS6. Well-described founder
mutations in GLE1, BBS10, B3GLCT, MKS1, and EXOSC3 were
identiﬁed in 5 families. The MKS1 variant was identiﬁed
through a gene panel analysis as the MAF is greater than
0.001, and the nomenclature recorded in HGMD Pro for this
founder mutation is discordant with the Alamut annotation.
Rare LRP4missense variants, p.(Asp606Asn) and p.(Gly629Glu),
were identiﬁed in case 9. Pathogenic variants in this gene are a
known cause of Cenani-Lenz syndrome, which is
characterized by syndactyly/oligodactyly and kidney
abnormalities.24 Sanger sequencing conﬁrmed that the
affected fetus was compound heterozygous for the missense
variants. In silico tools supported pathogenicity of both
missense variants, which lie within conserved LDLR receptor
class B repeats 3 and 4, respectively, of LRP4. The PROSITE
database entry for the LDLR receptor class B repeat (entry
PS51120) contains 683 repeats from 62 different proteins;
alignment of LRP4 repeats 3 and 4 with the consensus
sequence shows that the p.(Asp606Asn) and p.(Gly629Glu)Ta
bl
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variants lie at positions 40 and 20 of the repeat motif,
respectively (Figure 4). Inspection of the PROSITE sequence
logo indicated that aspartic acid and glycine are the most
commonly observed amino acids at these positions (at
frequencies of ~68% and ~79%, respectively), whereas the
variant residues were absent or present at very low
frequencies (≤1.5%). By comparison, a previously reported
pathogenic LRP4 missense variant, p.(Asp529Asn),24 occurs
at position 7 of the motif within the second LDLR receptor
class B repeat, and although aspartic acid is most commonly
seen at this position (~81% frequency in the sequence logo),
the variant residue asparagine is observed in 41/683 sequences
in the PROSITE entry (6%). This suggests that the p.(Asp529Asn)
is more likely to be tolerated than the variants identiﬁed in this
couple and thus have a milder effect on structure and function
of the repeat resulting in a less severe phenotype.
Messenger RNA analysis was undertaken for a couple with
novel IFT122 variants (case 7). The paternal variant was a large
insertion-deletion that results in the net loss of 5 amino acids
in exon 17 of the IFT122 gene and is predicted to result in
signiﬁcant changes to the arrangement of secondary structure
motifs. The maternal variant was a base substitution,
c.3039+4A>G, in intron 24 (Figure 5A), and the splice
prediction tools suggest a reduction in the strength of the 50
acceptor site of between 9.1% and 30%. Sanger sequencing of
PCR products generated by using primers designed to amplify
from exon 23 to exon 25 of cDNA from the carrier mother is
consistent with exon 24 skipping (Figure 5B).
An additional, or unsolicited, ﬁnding was identiﬁed in 1
consanguineous couple who are both heterozygous carriers
of a pathogenic frameshift variant, c.3503_3504del, p.
(Leu1168fs) in the GNPTAB (NM_024312.4) gene. This is a
previously reported founder mutation, and recessive variants
are a known cause of Mucolipidosis II alpha/beta.25,26
DISCUSSION
Using the parental autosomal recessive strategy, a potential
genetic diagnosis was established in 26/50 couples, giving a
Figure 2 (A) The overall diagnostic yield in the 50 couples included in this audit. (b) The diagnostic yield for couples with 2 or more affected
pregnancies. (C) The diagnostic yield for couples with a single affected pregnancy
Figure 3 Pie charts to show the phenotypic spectrum for (A) all couples referred for testing by using this strategy and (B) the 26 couples with a
genetic diagnosis
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diagnostic yield of 52%. This increases to 18/29 (62%) in
those couples who have had 2 or more pregnancies affected
with lethal or prenatal-onset disorders. Potentially
pathogenic variants were identiﬁed in 24 different genes,
consistent with the known genetic heterogeneity of these rare
disorders. By using the parental DNA for exome sequencing,
we can conserve the precious DNA from the affected
pregnancies; using a small quantity for directed variant
conﬁrmation.
In most cases, the reported phenotypes in these families
were consistent with that reported in the literature. Some cases
identiﬁed a diagnosis that would not usually be readily
identiﬁed in the prenatal period. A diagnosis of Peters-plus
syndrome was made in family 21 after the identiﬁcation of
the founder mutation, c.660+1G>A, in the B3GLCT gene
(formerly known as B3GALTL). A diagnosis of Peters-plus
syndrome is often made postnatally; prenatal diagnosis has
been reported but is generally more difﬁcult due to variable
and nonspeciﬁc ﬁndings.27 Severe hydrocephalus was the only
indication of this diagnosis. Similarly, the fetuses with the
POMGNT1 homozygous missense variant had presented with
ventriculomegaly, an early feature of muscle-eye-brain disease
(case 28).
Other cases conﬁrmed an extension of a known phenotype
or evidence of a genotype-phenotype correlation. LRP4
missense variants, p.(Asp606Asn) and p.(Gly629Glu), were
identiﬁed in case 9. Pathogenic missense or splicing LRP4
variants are a known cause of Cenani-Lenz syndrome, which
is characterized by a less severe phenotype than was seen in
our patient, of syndactyly/oligodactyly and kidney
abnormalities.24 A recent report of truncating variants
causing a severe lethal prenatal form28,29 is consistent with
Figure 5 (A) Location of the IFT122 variant, NC_000003.11(NM_052985.3)c.3039+4A>G, in intron 24. (b) Sequence electropherogram of
the IFT122 RT-PCR product demonstrating the effect of this splicing variant in the maternal RNA. The primers used were designed over the
suspected breakpoint (exon23-exon25 boundary) so only the variant allele was ampliﬁed
Figure 4 The upper panel shows an alignment of the YWTD repeats 2 to 4 of human LRP4 from PROSITE entry PS51120 (gaps removed),
highlighting the variants identiﬁed in case 9, p.(Gly629Glu) (yellow) and p.(Asp606Asn) (blue) and the previously reported p.(Asp529Asn)
(green). Representation of the sequence logo below indicates that the wild-type residues are the most commonly seen, whereas the variant
residues are either absent or present at a low frequency (≤1.5%)
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Cenani-Lenz syndrome being the result of hypomorphic
variants. This suggested that some missense variants could
have a severe impact on protein function and result in a
severe lethal prenatal phenotype. The p.Asp606 and p.
Gly629 residues are located within the highly conserved
LRP4 YWTD motif. Variant residues at these positions are
either absent or rarely observed in this sequence and are
unlikely to be tolerated within the repeat region. A missense
variant, p.(Asp529Asn), reported in a patient with Cenani-
Lenz syndrome24 is observed at a frequency of ~6%, and
although this variant is known to be pathogenic, it is clearly
compatible with life. We predict that both p.(Asp606Asn) and
p.(Gly629Glu) may have a more severe effect, consistent with
observed lethality in the case of the fetuses with compound
heterozygosity for these 2 variants.
Similarly, recessive pathogenic IFT122 variants are known
to cause Cranioectodermal dysplasia 1,30 which is a nonlethal
condition where patients present with craniofacial, skeletal,
and ectodermal abnormalities. One couple has been reported
with recurrent pregnancy losses and compound
heterozygosity for 2 IFT122 mutations (a missense and
frameshift).31 More recently, IFT122 biallelic variants, a
missense and a frameshift, were identiﬁed in a male infant
born prematurely at 31/40 weeks of gestation with a typical
phenotype of short-rib polydactyly type IV.32 We found
compound heterozygous IFT122 variants in 1 family (case 7)
with a skeletal dysplasia. The paternally inherited variant
was a large insertion-deletion in exon 17 of IFT122. In-frame
insertions and deletions in nonrepetitive regions of greater
than 1 amino acid are considered more likely to disrupt
protein function than a missense variant alone; the larger
the deletion or insertion, the more likely it is to be
pathogenic.10 These large in-frame insertions/deletions are
rare in population databases reﬂecting the fact that they
generally have deleterious effects on protein structure and
folding, particularly when they overlap or occur within
regions of secondary structure. In silico tools predicted
aberrant splicing due to a maternal variant, c.3039+4A>G in
intron 24, and messenger RNA studies supported that
prediction with skipping of exon 24 observed in a maternal
blood sample. Thus, evidence suggests that these 2 variants
are likely to be pathogenic and provide a plausible
explanation of the phenotype seen in their affected offspring.
This case also illustrates the extended spectrum of
phenotypes associated with known disorders identiﬁed due
to exome sequencing.
In 3 families, a “clinical exome” test was performed where a
subset of the exome was sequenced (~6110 genes) and a
genetic diagnosis was established in 2 of the 3 families. We
recommend that WES is undertaken for the undiagnosed
couple because in our cohort, 3 of the 26 diagnoses made by
using the whole exome capture would have missed using this
“clinical exome” approach targeting 6,110 genes associated
with human diseases (genes known at the time of the capture
design in 2013).
A novel SASS6 variant, p.(Glu412Gly), was identiﬁed in both
partners of a couple who had 2 pregnancies with primary
microcephaly (case 14). This gene has recently been identiﬁed
by homozygosity mapping using WES in a large
consanguineous Pakistani family with multiple family
members affected with microcephaly.33 Homozygous NEK9
variants were identiﬁed in family 39 who were known to be
consanguineous and had 2 affected pregnancies with
arthrogryposis and fetal akinesia sequence. In 2016, this gene
was linked to lethal contracture syndrome type 10 in 2 Irish
traveler families.34 Couple 41 suffered 2 pregnancy losses at
birth; both babies had no respiratory effort and congenital
hypertrophic cardiomyopathy. Both affected offspring were
compound heterozygous for an ATAD3A novel missense
variant and a deletion of exons 3 and 4. Monoallelic and
biallelic variants have recently been reported to cause Harel-
Yoon syndrome, which is characterized by global
developmental delay, hypotonia, optic atrophy, axonal
neuropathy, and hypertrophic cardiomyopathy.35 Compared
with the whole exome test, the clinical exome is cheaper, yields
a shorter list of variants for analysis, and may give higher
coverage across known disease genes but, as demonstrated in
these 3 cases, has the disadvantage of not including the most
recently discovered, or not yet identiﬁed, disease genes.
Using this strategy, only shared genes where both parents
harbor a rare variant are included in the analysis; this limits
the risk of detection of a variant in later-onset dominant
disorders, such as cancer predisposition genes. However, this
approach does not exclude the possibility of revealing carrier
status for other autosomal recessive disorders and this
risk is increased in consanguineous couples. In one of the
consanguineous couples in this case series, we identiﬁed an
additional, unrelated ﬁnding where both parents were
heterozygous for a founder mutation in the GNPTAB gene. As
this is a clearly pathogenic variant, we discussed it with the
referring clinician who agreed to disclose the ﬁnding due to
the 1 in 4 risk for this couple having a child affected with
Mucolipidosis II alpha/beta in addition to the 1 in 4 risk of
inheriting the variants causative of the recessive condition that
had already presented. We note that if there had been
sufﬁcient DNA available for a trio analysis, this additional
ﬁnding might not have been detected. The couple found the
information on the incidental ﬁnding useful and informative.
There are multiple reasons why likely disease-causing
variants were not identiﬁed in 24 of the 50 families reported
here. It is reasonable to assume an autosomal recessive pattern
of inheritance in a family with multiple affected offspring or in
a consanguineous pairing, but a different mode of inheritance
cannot be excluded. Recent case reports describe families with
multiple affected children with megacystis microcolon
intestinal hypoperistalsis syndrome, due to de novo disease-
causing variants in the ACTG2 gene, suggestive of gonadal
mosaicism.36 Similarly, diagnostic exome sequencing in 13
families with known consanguinity indicated that over 38% of
positive results were not autosomal recessive.37 One of the 11
couples tested who were known to be consanguineous each
had a different missense variant in the BBS9 gene that was
compound heterozygous in their affected fetus. Other
explanations for not identifying a diagnosis include that the
disorder is not monogenic, the pathogenic variant may be
noncoding, the pathogenic variant may be a structural variant,
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the disease gene may not yet be associated with a disease
phenotype, the causative gene may be poorly covered by the
capture, or pathogenic variants could have been ﬁltered out
by the bioinformatic strategy/software. Interpretation of
variants is based on information that is currently available,
and this is likely to change as knowledge increases. One of
the advantages of WES is that the data can be reanalyzed in
the future as new disease genes are annotated.2
CONCLUSION
In summary, we demonstrate that parental exome sequencing
is a powerful tool to diagnose lethal or prenatal-onset recessive
fetal disorders. For those couples where insufﬁcient fetal DNA
is available for exome sequencing, this strategy provides the
opportunity of a genetic diagnosis to provide preimplantation
or prenatal diagnosis for future pregnancies.
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WHAT’S ALREADY KNOWN ABOUT THIS TOPIC?
• Exome sequencing is used routinely for postnatal diagnosis of rare
disorders with a diagnostic yield of 20 to 40%.
• Insufﬁcient quantity or quality of DNA restricts the use of exome
sequencing for diagnosing lethal fetal disorders.
• Couples are counselled for a likely 25% recurrence risk, but without
a genetic diagnosis, no molecular prenatal test is possible.
• A parental exome sequencing strategy has been applied
successfully in a small number of couples.
WHAT DOES THIS STUDY ADD?
• We show that exome sequencing of parental DNA samples is an
effective way to diagnose lethal or prenatal-onset disorders with a
diagnostic yield of 52% in an audit of 50 consecutive cases.
• Testing can be carried out in the prenatal period to guide
management of an ongoing pregnancy or for use in subsequent
pregnancies to allow couples the option of a prenatal or
preimplantation genetic test.
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